FIELD: pharmacology.
SUBSTANCE: invention is a capsule composition for oral administration with an antifungal activity comprising an encapsulated material containing L-lysine-{[(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyldihydrogen phosphate-ethanol; and a capsule shell formed by the capsule shell base containing pullulan or hypromellose, wherein the weight ratio of L-lysine -{[(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyldihydrogen phosphate-ethanol to the capsule shell is 0.27 or more.
EFFECT: improved degree of capsules dissolution compared to gelatine capsules.
3 cl, 4 dwg, 3 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION | 2012 |
|
RU2630617C2 |
| PHARMACEUTICAL COMPOSITION | 2008 |
|
RU2470637C2 |
| STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING LEVOCETIRIZINE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND MONTELUKAST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2013 |
|
RU2614382C2 |
| ENCAPSULATED DOSAGE FORM, CONTAINING MONTELUKAST AND LEVOCETIRIZINE | 2012 |
|
RU2606857C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, DOSAGE FORM BASED ON PHARMACEUTICAL COMPOSITION COMPRISING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARING AND USING DOSAGE FORM BASED ON PHARMACEUTICAL COMPOSITION CONTAINING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2021 |
|
RU2818092C1 |
| PHARMACEUTICAL COMPOSITION OF IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD FOR PREPARING IT AND METHOD(S) OF TREATING | 2012 |
|
RU2517216C2 |
| BIOLOGICALLY ACTIVE FOOD SUPPLEMENT OF ENCAPSULATED FORM | 2020 |
|
RU2756855C1 |
| BIOLOGICALLY ACTIVE DIETARY SUPPLEMENT IN ENCAPSULATED FORM | 2020 |
|
RU2759731C1 |
| SUSTAINED-ACTION PHARMACEUTICAL COMPOSITION FOR TREATING HEART DISEASES | 2011 |
|
RU2464018C1 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
